Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cell-mediated Immune Responses

Cell-mediated Immune Responses

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes.

Diabetes·2026

Same author

Histological evidence of familial GH-PitNET associated with germline MAX mutation.

European journal of endocrinology·2026

Same author

Comparison between olfactory bulb and olfactory tract implantations through an endoscopic supraorbital keyhole approach: a cadaveric study.

Acta neurochirurgica·2025

Same author

Whole tissue spatial cellular analysis reveals increased macrophage infiltration in pancreata of autoantibody positive donors and patients with type 1 diabetes.

bioRxiv : the preprint server for biology·2025

Same author

A Tolerogenic Plasmid Inhibits Autoantibody Production Triggered by Immunization With Human Peptidyl Arginine Deiminase 4.

Arthritis & rheumatology (Hoboken, N.J.)·2025

Same author

Meningeal Embolization for Preventing Chronic Subdural Hematoma Recurrence After Surgery: The EMPROTECT Randomized Clinical Trial.

JAMA·2025

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation

Published on: August 13, 2013

Resuscitating adaptive Tregs with combination therapies?

Damien Bresson¹, Matthias von Herrath

¹Developmental Immunology-3, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA.

Novartis Foundation Symposium

|February 11, 2009

Summary

Inducing adaptive regulatory T cells (Tregs) via vaccination shows promise for type 1 diabetes (T1D). Combining Treg vaccines with immune modulators like anti-CD3 may achieve long-term tolerance and a potential cure.

Area of Science:

Immunology
Endocrinology
Autoimmunity

Background:

Adaptive regulatory T cells (Tregs) hold potential for preventing type 1 diabetes (T1D) through antigen-specific vaccination.
Current translation to clinical application for T1D immune tolerance remains a significant challenge.
Immune responses involve a balance between effector cells and Tregs, crucial for maintaining homeostasis.

Purpose of the Study:

To explore the optimal timing and routes for islet antigen vaccination to enhance adaptive Tregs.
To investigate methods for 'resuscitating' Tregs for sustained immune tolerance in the islet micro-environment.
To propose combination therapies for effective immune-based intervention in T1D.

Main Methods:

Analyzing the dynamics of effector and Treg populations during T1D development.

More Related Videos

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Related Experiment Videos

Last Updated: Jun 25, 2026

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation

Published on: August 13, 2013

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Evaluating the impact of systemic immune modulators, such as anti-CD3, on Treg propagation.

Developing strategies for combining Treg-inducing vaccines with immune modulators.

Main Results:

The timing and route of islet antigen administration significantly influence Treg augmentation efficiency.
Systemic administration of non-Fc-binding anti-CD3 promotes Treg propagation by creating a favorable milieu.
Short-term systemic immune modulation can enhance adaptive Treg induction.

Conclusions:

Combination therapies involving Treg vaccines and systemic immune modulators represent a promising strategy for T1D intervention.
Enhancing adaptive Tregs is critical for achieving long-term immune tolerance and homeostasis in T1D.
Resuscitating Tregs is a key step towards a potential cure for type 1 diabetes.